FDA Calls For More Review Of Aortic Valve Reduced Leaflet Motion
This article was originally published in The Gray Sheet
Executive Summary
The agency issued a notification that recent advanced imaging studies have shown reduced leaflet motion in bioprosthetic aortic valves. While FDA believes the devices are reasonably safe and effective, it is working with cardiology societies to design new clinical studies to explore the phenomenon.
You may also be interested in...
Boston Scientific Pulls All Lotus TAVR Systems Off Shelves
The worldwide voluntary removal comes in response to reports that the pin that connects the valve to the delivery system sometimes releases prematurely, most likely due to excess tension created during manufacturing.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.